Drug boosts hemoglobin but not survival in heart failure study

03/12/2013 | Forbes

In patients with systolic heart failure and mild-to-moderate anemia, treatment with the erythropoiesis-stimulating agent Aranesp, or darbepoetin alfa, boosted hemoglobin levels but did not improve patient outcomes, according to a study in the New England Journal of Medicine. "Our findings suggest that the hemoglobin level, like other surrogates, is simply a marker of poor prognosis in heart failure rather than a therapeutic target," researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC